Apellis Pharmaceuticals - Company Information
At apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body's immune system. our work is rooted centrally at c3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. targeting c3 has broad platform potential to treat many diseases where patients have few or no treatment options available. our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting c3. for more information, please visit http://apellis.com.
Biotechnology
Apellis Pharmaceuticals - Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by Sprouts.ai, used by Apellis Pharmaceuticals.
Materialize
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Javascript
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Vue.js
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
TweenMax
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Polyfill
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
PHP
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Employee profile
John Doe
CEO
Samantha Duncan
CTO
Gary Austin
MD
Jonathan Shaw
CMD
Janice May
MD
Janet McDonald
CFO
Apellis Pharmaceuticals - Company Information
At apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body's immune system. our work is rooted centrally at c3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. targeting c3 has broad platform potential to treat many diseases where patients have few or no treatment options available. our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting c3. for more information, please visit http://apellis.com.
Biotechnology
Apellis Pharmaceuticals - Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by Sprouts.ai, used by Apellis Pharmaceuticals.
Materialize
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Javascript
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Vue.js
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
TweenMax
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Polyfill
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
PHP
Some quick example text to build on the card title and make up the bulk of the card&aposs content.
Employee profile
John Doe
CEO
Samantha Duncan
CTO
Gary Austin
MD
Jonathan Shaw
CMD
Janice May
MD
Janet McDonald
CFO
